cancer immunotherapy

News
BMS_Nassau_Park

BMS makes record $1.8bn bet on Nektar cancer drug

Bristol-Myers Squibb scored a first-in-class approval with cancer immunotherapy Opdivo just a few years ago – could it be about repeat the trick with a new drug that stimulates natural kill